Lead Sponsor

Reckitt Benckiser Healthcare (UK) Limited

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Yes

•1. Patient with a primary diagnosis of symptomatic GORD in accordance with the Montreal definition. Patients must have experienced frequent troublesome heartburn and / or regurgitation (with or without dyspepsia symptoms) of mild/moderate intensity. If the patient also has other symptoms, the heartburn, regurgitation or dyspepsia should be the predominant symptoms.
•2. Patient that are healthy (with the exception of a diagnosis of GORD) as determined by past medical history and vital signs at screening.

•1. Patients with a history or active gastrointestinal disease (gastroduodenal ulcer, gastrointestinal haemorrhage, mechanical obstruction or perforation) or hiatus hernia which is greater than 3 cm or a history of conditions that can lead to abnormal oesophageal pH.
•2. Patients experiencing frequent troublesome heartburn and / or regurgitation (with or without dyspepsia symptoms) of severe intensity
•3. Patients who are unwilling to refrain from using antacids or alginates 24 hours prior to the start of the treatment visit.
•4. Patients who are unwilling to refrain from using proton pump inhibitors (PPIs), H2 antagonists, motility stimulants or other medicines for relief of symptoms of acid reflux disease 2 weeks prior to the start of treatment period.

Related studies

NCT05745857 · Barrett's Esophagus Without Dysplasia, Barrett Oesophagitis With Dysplasia, and more

NCT07112378 · Eosinophilic Esophagitis (EoE)

NCT06693531 · Eosinophilic Esophagitis (EoE)

NCT05199532 · Eosinophilic Esophagitis, Eosinophilic Gastroenteritis, and more

NCT06596252 · Eosinophilic Esophagitis

Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum